Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Announces that November 2017 was the Largest Revenue Sales Month in Company History

Medical Marijuana,Inc.
Posted on: 13 Dec 17
Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Announces that November 2017 was the Largest Revenue Sales Month in Company History

PR Newswire

SAN DIEGO, Dec. 13, 2017

SAN DIEGO, Dec. 13, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that subsidiary HempMeds® Mexico generated the largest-ever revenue month in the history of the company in November of 2017, as well as reached major milestones in its business operations.

HempMeds® Mexico is Medical Marijuana, Inc.'s distribution branch in the country, focusing on providing non-psychoactive cannabidiol products to the people in Mexico. HempMeds® Mexico was the first company to have a medical cannabis product approved for import into Mexico, a country that is in the process of restructuring their policies regarding cannabis.

In order to import its CBD hemp oil to Mexico, the Company had to develop a product completely free of THC. They achieved this by isolating the CBD within its hemp oil, thus eliminating the trace amounts of THC in its hemp oil to make RSHO-X™.

In November, the company's president, Raul Elizalde, spoke to the United Nations at the World Health Organization's Expert Committee Meeting on Drug Dependence, where he urged top global leaders not to schedule CBD as a drug, but rather as a supplement. His appearance gained international media attention and raised awareness for the global need for the expansion of access to CBD.

Elizalde also represented HempMeds® Mexico at the Second International Fair on Medical Cannabis in Colombia. There, he spoke to patients and doctors about the Company's success and how its products may provide therapeutic benefits to Colombian citizens.

"Our success in Mexico is tremendously important to the Medical Marijuana, Inc. portfolio of companies as we continue to expand our international reach," said HempMeds® Mexico President, Raul Elizalde. "Mexico has experienced many CBD regulation changes this year and we're proud to come out of them on top."

This December, Mexican health authorities will publish cannabis regulations for the Mexican market, creating many new investment opportunities and allowing cannabis research to be conducted and cannabis products to be distributed as medicines, herbal remedies, supplements and food.

About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company's website at:

About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit

To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease.  The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.


Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829- 0070


View original content:

SOURCE Medical Marijuana, Inc.

PR Newswire

Last updated on: 13/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.